Posts Tagged ‘Deep vein thrombosis’
Stephan Moll, MD writes… This month the American College of Chest Physicians (ACCP) published its new (2012) guidelines regarding anticoagulation and management of various thrombotic disorders, replacing the 2008 edition. The details of the new guidelines can be found here Read the rest of this entry »
Xarelto (Rivaroxaban) was approved in Europe today (Dec 19th, 2011) for patients with acute DVT. This is good news Read the rest of this entry »
A new guideline was published this week about venous thromboembolism (VTE) prophylaxis in hospitalized medical sick patients and in stroke patients [link here; ref 1].
The key points of this guideline, Read the rest of this entry »
Two main guidelines exist which many physicians go by to decide whether a particular patient should get DVT prophylaxis after hip or knee replacement surgery, what method (compression device, or pharmacologic agent) to use, and for how long to give prophylaxis. (a) One is the ACCP guideline (American College of Chest Physicians), last published in June 2008 [ref 1]. An updated version is expected to be published around February 2012. (b) The other one is the AAOS guideline Read the rest of this entry »
It has long been known that estrogen-containing birth control preparations (pill, patch, ring) increase the risk for DVT and PE (venous thromboembolism = VTE). This risk is partially due to the estrogen. However, part of the risk is also due to the type of progestin in these preparations. Read the rest of this entry »
CT or MRI scans will occasionally detect an incidental iliofemoral DVT, PE or intra-abdominal thrombosis (IVC, portal, splenic, mesenteric or renal vein). This is particularly common in cancer patients undergoing staging CT scans. When such an incidental, asymptomatic venous thromboembolism (VTE) is discovered, the question arises whether the patient should be treated with anticoagulants or not. Read the rest of this entry »
Explanation for Patients
The complex topic of “Length of Anticoagulant Treatment” for patients with VTE is being addressed in a blog entry written for patients, found on the Clot Connect patient education blog (here).
For the Health Care Professional
Well respected treatment guidelines exist [ref 1,2]. Read the rest of this entry »
Good news. Another one of the new oral anticoagulants in development, Apixaban (Eliquis®), has moved forward. On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval Read the rest of this entry »
Many people think of DVT and PE as a problem occurring in elderly people, but not in young and apparently healthy individuals. While it is certainly true that they occur more commonly in the elderly and in non-athletic overweight individuals, they can, nevertheless, happen in young, normal weight, and athletic people. Read the rest of this entry »
Testosterone Replacement Therapy
Replacement therapy with low doses of testosterone does not adversely affect blood coagulation status [ref 1] and does not appear to increase the risk of venous or arterial thrombosis. Thrombosis is not listed as a potential side effect in the commly used drug compendium (Micromedex). Furthermore, the 2006 “Clinical Practice Guideline” from the Endocrine Society also does not list thrombosis as a side effect of testosterone replacement therapy, or a previous history of blood clots as a reason not to give testosterone replacement therapy [ref 2]. However, the Androgel® package insert (prescribing information) lists “blood clots in the legs” as a potential side effect Read the rest of this entry »